PATIENT GROUP SUBMISSIONS to BC PharmaCare and CADTH

PATIENT GROUP SUBMISSIONS to BC PharmaCare and CADTH Whenever we are asked to contribute a patient group submission about a hepatitis-C or hepatitis-B related product, we do so. We contribute as a patient group to reviews by both BC PharmaCare (to determine whether BC PharmaCare patients will be reimbursed for the drugs) and CADTH (federal level – to determine whether the drugs will be available in Canada). Below are the submissions we have made, from

Current Treatments

Current HCV Treatments in BC as of March 2019 IMPORTANT: As of March 13, 2018,  anyone in B.C. living with this now-curable virus will have a choice of several treatment options – all of which are fully funded under BC PharmaCare, and all restrictions based on disease level have been removed. There are many drug combinations available for treating hepatitis C in Canada which are also covered by BC Pharmacare.  Older combinations involved the use of i

AbbVie’s TECHNIVIE™ Receives Health Canada Approval for Genotype 4 Chronic Hepatitis C Infection

TECHNIVIE provides an opportunity to treat adults who have genotype 4 (GT4) chronic hepatitis C virus (HCV) infection without cirrhosis, a population historically considered difficult–to-treatTECHNIVIE is the first and only all-oral, interferon-free, direct-acting antiviral treatment approved in Canada for adult patients with GT4 chronic HCV infectionApproval is supported by a Phase II clinical trial of 135 chronic HCV GT4 patients, which demonstrated 100

Information Update – Risk of Serious Liver Injury associated with Hepatitis C Treatments: Holkira Pak and Technivie

OTTAWA, Nov 10, 2015 /CNW/ - In response to new international safety information, Health Canada is advising Canadians that it is working with the manufacturer of Holkira Pak and Technivie to update drug labels (product monographs) to include new information regarding serious liver injury.Holkira Pak and Technivie are both used to treat chronic Hepatitis C viral infection that can lead to serious liver and health problems, including cirrhosis, liver cancer,

FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie

Oct 22, 2015The U.S. Food and Drug Administration (FDA) is warning that hepatitis C treatments Viekira Pak [Holkira Pak in Canada] and Technivie can cause serious liver injury mostly in patients with underlying advanced liver disease. As a result, we are requiring the manufacturer to add new information about this safety risk to the drug labels.Patients taking these medicines should contact their health care professional immediately if they develop fatigue